Merck Inc announced that the FDA has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients… read more.
Article written by Gary Finnegan. Survival rates among people living with HIV have soared over several decades, thanks to antiretroviral therapies. However, as maintaining long-term treatment can be… read more.
CMR Surgical (CMR) – a global surgical robotics business – announced the expanded use of its next-generation surgical robotic system Versius in Europe. For the first time, Versius… read more.
Article written by Gary Finnegan. Chronic kidney disease affects approximately 700 million people worldwide with many going on to require dialysis. Now a new enzyme has been discovered… read more.
Merck Inc., hosted on 3 May an Organon management investor day meeting, to detail across women’s health, biosimilars and established brands.The new company will be launched on 3… read more.
Article written by Gary Finnegan. A study that screened children for early-stage type 1 diabetes has detected a rate of COVID-19 infection higher than the number of cases… read more.
GlaxoSmithKline plc announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult… read more.
Article written by Gary Finnegan. It is well-established that the children of people with serious mental health issues can be affected by their parents’ illness. Now new research… read more.
Pfizer Canada ULC and BioNTech SE announced that Health Canada has expanded the Interim Order authorization for their COVID-19 vaccine to include individuals 12 to 15 years of… read more.
Article written by Gary Finnegan. The European Medicines Agency’s (EMA) key committee, known as the CHMP, has recommended approval of eight medicines at its latest meeting. While the… read more.
Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening… read more.
Article written by Gary Finnegan. The European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) has unveiled a new initiative aimed at strengthening post-marketing monitoring… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
